Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) in t(11;14) Multiple Myeloma
Latest Information Update: 04 Dec 2024
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 04 Mar 2024 Status changed from not yet recruiting to recruiting.
- 28 Feb 2024 Planned initiation date changed from 1 Feb 2024 to 1 Apr 2024.
- 04 Jan 2024 Planned End Date changed from 1 Sep 2028 to 1 Dec 2028.